After Veeva (VEEV) highlighted in a post to its corporate LinkedIn page GSK‘s (GSK) successful Vault CRM go-live across Europe, Raymond James notes that GSK discussed the reasons for opting for Veeva’s Vault CRM, including unlocking the quickest route to AI, which the firm finds “particularly interesting.” The firm, which calls the rollout “a key milestone for Veeva,” given that a top 20 pharma is now live at scale, compares this to Salesforce (CRM), which it argues will likely have no such reference customer live until the 2029 time frame.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VEEV:
- Options Volatility and Implied Earnings Moves This Week, August 25 – August 29, 2025
- VEEV Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Cautious Outlook on Veeva Systems Amid Growth Sustainability Concerns and Sector Risks
- Veeva Systems: Hold Rating Amid High Expectations and Macroeconomic Concerns
- Veeva price target raised to $268 from $230 at Truist